InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Thursday, 06/20/2019 9:50:46 AM

Thursday, June 20, 2019 9:50:46 AM

Post# of 6725
News: $ABUS Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729

- AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production - Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral capsid inhibitor WARMINSTER, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biop...

Find out more https://marketwirenews.com/news-releases/arbutus-receives-regulatory-clearance-to-initiate-phase-1a-1b-clinical-trial-of-ab-729-8388162.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABUS News